NNC0487-0111 for Obesity and Heart Failure

(HF-POLARIS Trial)

This trial tests the safety and effectiveness of a new medicine, NNC0487-0111, for individuals with certain types of heart failure and excess body weight. The study compares the effects of NNC0487-0111 to a placebo, administered by injection once a week. Participants are randomly assigned to receive either the new medicine or the placebo. The trial seeks individuals diagnosed with heart failure and a Body Mass Index (BMI) of 30 or higher, indicating excess body weight. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that NNC0487-0111, also known as Amycretin, is generally safe for people. Studies have found it well-tolerated by individuals who are overweight or have obesity, with no new safety concerns reported. Participants took the treatment once a week, which most found manageable. While ongoing studies continue to monitor its safety, the results so far are promising. This treatment works by activating certain proteins in the body to help control weight. Overall, current evidence indicates that the treatment appears safe and well-tolerated.¹²³⁴⁵

NNC0487-0111 is unique because it targets both obesity and heart failure, making it a promising dual-purpose treatment. Unlike standard treatments that typically focus on either managing weight or improving heart function separately, this drug offers a combined approach. It is administered subcutaneously in a dose-escalating manner, which could provide more controlled and potentially more effective results. Researchers are particularly excited about its ability to address these two interconnected conditions simultaneously, which could lead to better overall patient outcomes.

Research has shown that NNC0487-0111, a new treatment tested in this trial, might help with obesity and heart failure. Earlier studies found that it can lead to weight loss, with some individuals losing up to 22% of their body weight. This treatment combines two hormones, GLP-1 and amylin, which work together to control hunger and enhance the body's energy use. Early results suggest it could be promising for heart failure by potentially improving heart function and reducing obesity-related issues. Although more research is needed, these initial findings are encouraging. Participants in this trial will receive either NNC0487-0111 or a placebo.¹⁶⁷⁸⁹